Skip to main content Skip to office menu Skip to footer
Minnesota Legislature

Office of the Revisor of Statutes

HF 1306

2nd Engrossment - 80th Legislature (1997 - 1998) Posted on 12/15/2009 12:00am

KEY: stricken = removed, old language.
underscored = added, new language.

Bill Text Versions

Engrossments
Introduction Posted on 03/10/1997
1st Engrossment Posted on 02/06/1998
2nd Engrossment Posted on 02/12/1998

Current Version - 2nd Engrossment

  1.1                          A bill for an act 
  1.2             relating to health; requiring health plan coverage for 
  1.3             off-label use of drugs; proposing coding for new law 
  1.4             in Minnesota Statutes, chapter 62Q.  
  1.5   BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA: 
  1.6      Section 1.  [62Q.525] [COVERAGE FOR OFF-LABEL DRUG USE.] 
  1.7      Subdivision 1.  [SCOPE OF COVERAGE.] This section applies 
  1.8   to all health plans, including the coverages described in 
  1.9   section 62A.011, subdivision 3, clauses (7) and (10), that are 
  1.10  issued or renewed to a Minnesota resident.  
  1.11     Subd. 2.  [DEFINITIONS.] (a) For purposes of this section, 
  1.12  the terms defined in this subdivision have the meanings given 
  1.13  them.  
  1.14     (b) "Medical literature" means articles from major peer 
  1.15  reviewed medical journals that have recognized the drug or 
  1.16  combination of drugs' safety and effectiveness for treatment of 
  1.17  the indication for which it has been prescribed.  Each article 
  1.18  shall meet the uniform requirements for manuscripts submitted to 
  1.19  biomedical journals established by the international committee 
  1.20  of medical journal editors or be published in a journal 
  1.21  specified by the United States Secretary of Health and Human 
  1.22  Services pursuant to United States Code, title 42, section 
  1.23  1395x, paragraph (t), clause (2), item (B), as amended, as 
  1.24  acceptable peer review medical literature.  Each article must 
  1.25  use generally acceptable scientific standards and must not use 
  2.1   case reports to satisfy this criterion. 
  2.2      (c) "Off-label use of drugs" means when drugs are 
  2.3   prescribed for treatments other than those stated in the 
  2.4   labeling approved by the federal Food and Drug Administration.  
  2.5      (d) "Standard reference compendia" means:  
  2.6      (1) the United States Pharmacopeia Drug Information; or 
  2.7      (2) the American Hospital Formulary Service Drug 
  2.8   Information. 
  2.9      Subd. 3.  [REQUIRED COVERAGE.] (a) Every type of coverage 
  2.10  included in subdivision 1 that provides coverage for drugs may 
  2.11  not exclude coverage of a drug for the treatment of cancer on 
  2.12  the ground that the drug has not been approved by the federal 
  2.13  Food and Drug Administration for the treatment of cancer if the 
  2.14  drug is recognized for treatment of cancer in one of the 
  2.15  standard reference compendia or in one article in the medical 
  2.16  literature, as defined in subdivision 2.  
  2.17     (b) Coverage of a drug required by this subdivision 
  2.18  includes coverage of medically necessary services directly 
  2.19  related to and required for appropriate administration of the 
  2.20  drug.  
  2.21     (c) Coverage required by this subdivision does not include 
  2.22  coverage of a drug not listed on the formulary of the coverage 
  2.23  included in subdivision 1. 
  2.24     (d) Coverage of a drug required under this subdivision must 
  2.25  not be subject to any copayment, coinsurance, deductible, or 
  2.26  other enrollee cost-sharing greater than the coverage included 
  2.27  in subdivision 1 applies to other drugs. 
  2.28     (e) The commissioner of commerce or health, as appropriate, 
  2.29  may direct a person that issues coverage included in subdivision 
  2.30  1 to make payments required by this section.  
  2.31     Subd. 4.  [CONSTRUCTION.] This section must not be 
  2.32  construed to:  
  2.33     (1) alter existing law limiting the coverage of drugs that 
  2.34  have not been approved by the federal Food and Drug 
  2.35  Administration; 
  2.36     (2) require coverage for any drug when the federal Food and 
  3.1   Drug Administration has determined its use to be 
  3.2   contraindicated; 
  3.3      (3) require coverage for experimental drugs not otherwise 
  3.4   approved for any indication by the federal Food and Drug 
  3.5   Administration; or 
  3.6      (4) reduce or limit coverage for off-label use of drugs 
  3.7   otherwise required by law or contract. 
  3.8      Sec. 2.  [EFFECTIVE DATE; APPLICATION.] 
  3.9      Section 1 is effective January 1, 1999, and applies to 
  3.10  coverage issued or renewed on or after that date.